Kornimate/medical-research-clean huggingface dataset:
idiopathic generalized epilepsy syndromes

Conditions: Epilepsy; Epilepsy, Idiopathic Generalized

Summary: the idiopathic generalized epilepsies (iges) have historically included the syndromes childhood absence epilepsy (cae), juvenile absence epilepsy (jae), juvenile myoclonic epilepsy (jme), and epilepsy with generalized tonic-clonic seizures alone (gtca). recognition of the iges is important for clinical care, as it informs diagnosis, prevents unnecessary investigation, allows optimal selection of anti-seizure medications (asms), and provides prognostic guidance. according to the new ilae definition in 2022, the study aims to describe the clinical features, electroencephalographic, imaging findings and long-term prognosis.

the long-term prognosis include the rate of drug-resistent epilepsy, relapse after drug withdrawn, common comorbidities such as mood disorders, attention deficit hyperactivity disorder (adhd) and learning disabilities.

Eligibility criteria:
inclusion criteria: * patients are consecutively and prospectively enrolled from epilepsy center, with newly diagnosed epilepsy or established epilepsy. * patients have a diagnosis of idiopathic generalized epilepsy (ige), according to the 2022 diagnostic criteria. * comprehensive clinical information is collected, and 24 hour video-electroencephalography is performed. * sign the informed consent forms. exclusion criteria: * other epilepsy syndromes are considered during follow-up, such as genetic generalized epilepsy. * lost to follow-up
intranasal submucosal bevacizumab for epistaxis in hereditary hemorrhagic telangiectasia (hht)

Conditions: HHT; Morbus Osler; Epistaxis

Summary: in a case series intranasal submucosal bevacizumab has been shown to reduce epistaxis in patients suffering from hereditary haemorrhagic telangiectasia together with ktp laser therapy. the aim of this study is to evaluate the effectiveness of submucosal intranasal bevacizumab compared to placebo in a randomized double blind trial setting.


Eligibility criteria:
inclusion criteria: * diagnosed and staged hht (shovlin et al 2000) * age 18-80 * minimum of 2 episodes of epistaxis/ week * ability and willingness to complete diary and comply with study requirements. exclusion criteria: * uncontrolled hypertension (systolic blood pressure \> 150mmhg, diastolic blood pressure \> 90mmhg) * history of a thromboembolic event, including myocardial infarction or cerebral vascular accident * malignancy of the upper respiratory tract within the last year * recent (\<3 months) or planned surgery * proteinuria * nasal intervention (laser or cautery) in pretreatment phase * allergy to local anesthetic

Keywords: epistaxis osler weber rendu hht hereditary haemorrhagic telangiectasia
research for associated genes for gastric cancer in family member with affected first-degree relatives

Conditions: Gastric Cancer; Genetic Predisposition

Summary: familial gastric cancer accounts for 10% of all cases, but predisposing genetic variations is unknown except for cdh1 mutation. because germline mutation is believed to be a key aspect of cancer predisposition, we plan to recruit persons with 2 or more affected family members in three-generation pedigree. the investigators will perform a whole-exome sequencing using dna from blood samples of families including gastric cancer patients and non-gastric cancer patients

1\> patient selection enroll criteria: 1) gastric cancer patients and their first-degree relatives and 2) family with two or more gastric cancer patients within three-generation pedigree. a three-generation pedigree will be used for diagnostic consideration or risk assessment of rare variation. personal history will be acquired by questionnaire which asks smoking, alcohol intake, dietary preference, socioeconomic information and history of previous eradication of hp. for any family member with gastric cancer, age at diagnosis, histology type, methods of treatment or pathological reports will be evaluated. 2\> whole exome sequencing, variant annotation, filtering and prioritization after whole exome sequencing, functional annotation of genetic variants will be conducted using annovar. 3\> linkage analyses to perform variant and gene-based linkage analysis in pedigrees, data will be analyzed using pedigree-vaast. 4\> validation using a genechip

Eligibility criteria:
inclusion criteria : * gastric cancer patients and their first-degree relatives * members in family with two or more gastric cancer patients within three- generation pedigree exclusion criteria : * those who reject the enrollment
corticosteroid prophylaxis on the cardiopulmonary bypass-induced systemic inflammatory response

Conditions: Heart Valve Diseases; Systemic Inflammatory Response Syndrome

Summary: to observe the effect of glucocorticoid on the dynamic changes of monocyte subsets in the peripheral blood of valve disease patients undergoing cardiopulmonary bypass perioperatively.

systemic inflammatory response syndrome (sirs) is a common major complication of cardiopulmonary bypass. "emergency hematopoiesis" is the pathological process induced by the inflammation. the investigators previously confirmed that emergency hematopoiesis induced by cardiopulmonary bypass led to dynamic changes of quantities of monocyte subsets, there is a significant increase in the number of two monocyte subsets: 1) cd14highcd16+ monocyte with strong immunomodulatory activity; 2) cd14lowcd16- monocyte with potential ability of proliferation and differentiation. therefore, a new hypothesis risen: "the change of the function and the number of monocyte subsets induced by emergency hematopoiesis play an important role for sirs occurrence after cardiopulmonary bypass, correcting emergency hematopoiesis is a new breakthrough in the prevention and treatment of sirs." to identify the mechanism of function changed in different monocyte subsets during the pathogenesis of sirs, the research intended to target perioperative-period patients with heart valve replacement, monitor dynamically the number and phenotype of peripheral blood monocyte subsets by flow cytometry; sort out of different monocyte subsets for cell culture in vitro, observe the ability of proliferation and differentiation and effects between monocyte subsets and t lymphocyte; investigate the mechanism of immune function changes with antibody-blocking and compartment culture in patients; observe the impact of glucocorticoid treatment on the emergency hematopoiesis, offer new objects for evaluation of immune status in patients and provide new evidence for anti-inflammatory therapy . patients should be follow the protocol of cardiopulmonary bypass according to normal hospital routine practice. a total of 30 patients will be enrolled in this clinical trial.

Eligibility criteria:
inclusion criteria: * valve replacement under cardiopulmonary bypass exclusion criteria: * cardiopulmonary bypass time over 120 minutes * hyperlipidemia * diabetes mellitus * autoimmune diseases

Keywords: monocyte cardiopulmonary bypass cardiac surgery
efficacy and safety of two regimens of anti-vegf therapy in chinese patients with polypoidal choroidal vasculopathy

Conditions: Polypoidal Choroidal Vasculopathy

Summary: the study will evaluate the efficacy and safety of two different regimens of anti-vegf therapy (octa plus oct guided 3+prn vs. oct guided 3+prn) in chinese patients with pcv. this study is to provide long-term safety data in the treatment of chinese patients with pcv.


Eligibility criteria:
inclusion criteria: * written informed-consent before any evaluation * visual impairment due to pcv, including type 1 pcv and type 2 pcv. * 50 years old and older * chinese * for study eye: bcva between 20/30 and 20/320 on electronic visual acuity texting at the time point of both screening and baseline. exclusion criteria: * have stroke and myocardial infarction within 3 months before screening * any active periocular and ocular infection and inflammation (including blepharitis, conjunctivitis, keratitis, scleritis, uveitis, intraocular inflammation) while screening and baseline. * uncontrolled glaucoma (under treatment \[iop\] ≥ 30 mm hg or depend on researchers) while screening and baseline * neovascularization of iris and neovascular glaucoma while screening and baseline * any causes led to choroidal neovascularization except pcv (including icnv, central serous chorioretinopathy, ocular histoplazmoza and pathologic myopia) while screening and baseline * with structure injury (including vitreous macular traction,epiretinal membrane involving in central fovea,subretinal fibroplasia,laser scar and central fovea atrophy) within 0.5 optic disc diameter to the central of macula while screening and baseline, which may harm the improvement of vision by treatment according to researchers * any systemic anti-vegf medication(as avastin) use within 3 months before screening * any medication systemic use toxic to lens, retina and optic nerve, including iron amine, chloroquine/chloroquine (plaquenil ®), tamoxifen, phenothiazine and ethambutol * for study eye: used to accept following treatments for pcv within 3 months or accept following treatments more than three times before baseline: 1. anti-angiogenesis drugs (pegaptanib, ranibizumab, bevacizumab),vegf-trap; 2. anecortave acetate corticosteroids; 3. protein kinase c inhibitors, squalamine, sirna; 4. pdt, visudyne® treatment, external beam radiotherapy, local laser photocoagulation, vitrectomy, submacular surgery and transpupillary thermotherapy * any intraocular surgery (including yag laser) within 3 months before baseline or predicated within 6 months after baseline * intraocular or periocular treatment of corticosteroids within 3 months before baseline * for follow eye: any anti-angiogenesis treatment (including anti-vegf, like lucentis, avastin and kh902 ) within 3 months before baseline

Keywords: polypoidal choroidal vasculopathy optical coherence tomography angiography optical coherence tomography
trivalent influenza vaccine in preventing flu in patients with central nervous system tumors

Conditions: Central Nervous System Neoplasm

Summary: this pilot clinical trial studies trivalent influenza vaccine in preventing flu in patients with central nervous system (cns) tumors. flu vaccine may help the body build an effective immune response and help prevent flu in patients who are receiving chemotherapy for cns tumors

primary objectives: i. the primary objective of this pilot study is to assess the efficacy of influenza vaccination in patients with central nervous system tumors as defined by a four-fold increase in hemagglutinin inhibition (hi) titers from the pre-vaccination baseline. secondary objectives: i. a secondary objective of this pilot study is to assess the efficacy of influenza vaccination in patients with central nervous system tumors as defined by a serum post-vaccination hi titer of at least 1:40. ii. the secondary objectives of this pilot study include an assessment of the relationship between a variety of clinical factors and seroconversion following influenza vaccination. iii. subgroup analyses will include an investigation of seroconversion and treatment (actively receiving chemotherapy, radiation therapy or both), disease status (active treatment vs long term followup), and use and dose of glucocorticoids. tertiary objectives: i. an additional area of interest which will be further explored in this pilot study is an assessment of the relationship between serologic markers of immune function and response to vaccination. outline: patients receive trivalent influenza vaccine intramuscularly (im) on day 0. after completion of study treatment, patients are followed up at 14 days, 21 days, and 3 and/or 6 months.

Eligibility criteria:
inclusion criteria: * patients must have a clinical diagnosis of a primary central nervous system tumor * patients must be eligible to receive the influenza vaccine * patients must be able to provide written informed consent exclusion criteria: * patients unable to receive the influenza vaccine due to history of allergy to egg proteins, allergy to influenza vaccine component, acute febrile illness at the time of proposed vaccine administration, history of clinically or virologically confirmed influenza infection in the previous 6 months, contraindication to intramuscular injections, guillan-barré syndrome, or other contraindication to the vaccine * patients who have received the 2011-2012 annual influenza vaccine prior to being considered for enrollment on this study
neoadjuvant gemcitabine and fractionated, weekly cisplatin for muscle invasive bladder cancer and patients not candidates for high dose cisplatin

Conditions: Invasive Bladder Cancer; Bladder Cancer

Summary: the standard treatment of muscle invasive bladder cancer is to administer chemotherapy for approximately 3 months then to have surgery to remove the bladder. chemotherapy may reduce the size of the cancer in your bladder before surgery and can also help to reduce the chance that your bladder cancer will come back (metastasize) in other parts of your body after bladder surgery. this study will involve testing cisplatin in lower weekly doses with gemcitabine.the purpose of this study is to test the effects, good and bad, of low dose weekly cisplatin and gemcitabine.


Eligibility criteria:
inclusion criteria: 1. pathologically confirmed muscle-invasive urothelial (transitional cell) carcinoma of the bladder or upper genitourinary tract. 2. stage t2-t4a. patients may have nodal disease but there must be no evidence of distant metastases and patients must be candidates for radical cystectomy as determined by urologic surgeon (note from/confirmation by surgeon required). 3. no prior systemic therapy for urothelial carcinoma. prior intravesical therapy is allowed. 4. patients are determined by their treating oncologist to not be a candidate high dose cisplatin (\> 70mg/m2) due to medical comorbidities. 5. creatinine clearance (crcl or eccr)) \> 25 ml/min calculated using the cockcroft-gault formula 6. patients without serious medical risk factors involving any of the major organ systems such that the investigator considers it unsafe for the patient to receive the protocol treatment of this study with gemcitabine and weekly fractionated cisplatin. 7. preexisting neuropathy \< grade 2. 8. no prior invasive malignancy within the prior two years. however, prior history of non-muscle invasive bladder cancer and patients with an early stage malignancy that is not expected to require treatment in the next 2 years (such as early stage, resected breast cancer, or asymptomatic prostate cancer) are eligible. 9. ecog performance status 0 or 1. 10. age ≥ 18 years of age. 11. not pregnant and not nursing. women of child bearing potential must have a negative serum or urine pregnancy test (minimum sensitivity 25 iu/l or equivalent units of hcg) within 7 days prior to beginning of treatment. post-menopausal women (surgical menopause or lack of menses \>12 months) do not need to have a pregnancy test, please document status. 12. required initial laboratory values: * neutrophils ≥ 1,000/μl * platelet count ≥ 100,000/μl * total bilirubin ≤ 1.5 x uln. * ast (sgot) \& alt (sgpt) ≤ 3.0 x uln exclusion criteria: 1. metastatic disease. 2. prior hypersensitivity to platinums that in the investigators opinion would put the patient at risk if re-exposed 3. small cell cancer of the bladder or pure adenocarcinoma. patients with mixed histologies such as urothelial carcinoma with sarcomatoid features, squamous differentiation or adenocarcinoma are allowed as long as transitional cell cancer is the predominant pathologic subtype.
evaluation of efficacy and safety of single and multiple therapy of herbal medicine/chuna therapy on non-specific chronic low back pain: a study protocol for multicenter, 3-arm, randomized, single blinded, parallel group, incomplete factorial design, pilot study -

Conditions: Chronic Low Back Pain

Summary: the purpose of this trial is to investigate the efficacy and safety of herbal medicine with manipulation therapy on korean patients with chronic low back pain


Eligibility criteria:
inclusion criteria: * inpatients with chief complaint of low back pain in oriental rehabilitation medical center * age 19 - 65 * patients who have 4 \~7 cm of vas pain score; * ability to have normal communication * ability to give informed consent exclusion criteria: * patients with pain duration of 3 months or less * patients with progressive neurologic deficit or severe neurologic symptoms by slr test * patients diagnosed with serious pathology(s) which may cause low back pain (e.g. spinal metastasis of tumor(s), acute fracture, etc) * patients with spondylolisthesis or spondylolysis(diagnosed with grade ii or higher level) * patients currently taking steroids, immunosuppressants, medicine for mental illness or other medication(s) that may interfere with study results * patients with history of spinal surgery * patients with more severe pain than pain caused by low back pain * those who do not (cannot) abide by treatment and follow up due to the mental illness such as behavior disorder, depression, anxiety neurosis etc. * patients with history of medical malpractice case * patients with treatment history of low back pain within 1 month either km or wm * patients participating in other clinical studies within 3 months * pregnant patients or patients with plans of pregnancy or lactating patients * patients disagree to sign the informed consent form * patients deemed unsuitable for participating the trial by the researchers
china registry of non-disabling ischemic cerebrovascular events

Conditions: Transient Ischemic Attack; Minor Stroke

Summary: the burden of non-disabling ischemic cerebrovascular events (nice) is significantly increased. in order to achieve accurate risk stratification and effective treatments, developing new diagnostic, therapeutic, and prognostic strategies is indispensable. chinese registry of nice is a national multi-center prospective study aimed to explore the epidemiology, new biomarkers, risk factors and prognostic models.

the pathophysiology of transient ischemic attack (tia) and minor stroke is a continuous progression. tia and minor stroke exhibit the common substantial risk factors for early stroke recurrence and epidemiological characteristic. since tia and minor stroke may leave impermanent or mild neurological deficit, they are termed as non-disabling ischemic cerebrovascular disease (nice). the results of the china chronic disease and risk factor surveillance (ccdrfs) 2010 showed that the age-standardized prevalence of tia is 2.27%. estimated 23.9 million people may have experienced a tia in china. the tia knowing-rate is approximately 3.08% in chinese adults, only 5.02% received treatment and 4.07% received guideline recommended therapy. the second china national stroke registry (cnsr-ii) indicated that minor stroke accounted for 42.23% of all the hospitalized patients of ischemic stroke, which is much higher than that showed in cnsr-i (2007-2008). thus, it is imperative to develop new strategies to improve the diagnosis, risk prediction and appropriate management of nice. nice is an attractive researching area globally. according to the large quantities of nice patients in china and the low standardized therapeutic rate, the awareness of nice is largely insufficient. the purpose of the present study is to establish a multi-center national prospective database of nice, including clinical information and biological samples library and, to further explore the epidemiology, new biomarkers, risk factors, and prognostic models.

Eligibility criteria:
inclusion criteria: 1. ≥18 years old 2. elapsed time from last episode to registry \<48 hours exclusion criteria: 1. patients who refused to participate in the research, and patients who failed to complete the follow-up protocol. 2. patients with malignant tumors, or patients with severe liver or kidney disease, whose life expectancy is less than 1 year. 3. patients who received endovascular or thrombolytic therapy.

Keywords: transient ischemic attack minor stroke non-disabling ischemic cerebrovascular events biomarker epidemiology prognosis
effect of vr versus ct in sensorimotor function of upper extremity in chronic stroke patients

Conditions: Chronic Stroke

Summary: virtual reality (vr) therapy has shown promising results in improving sensorimotor function of the upper extremity in chronic stroke patients compared to conservative treatments. vr offers immersive, interactive environments that can enhance motivation and engagement in rehabilitation exercises.


Eligibility criteria:
inclusion criteria * patients with a confirmed diagnosis of chronic stroke (at least 6 months post-stroke). age: * upper extremity impairment: * ability to provide informed consent to participate in the study. exclusion criteria * severe communication difficulties that would impede the ability to follow instructions during therapy. * severe spasticity in the affected upper limb (modified ashworth scale score of 4 or higher). * other neurological conditions
co-administration of mk-4618 with antihypertensive agents (mk-4618-010)

Conditions: Hypertension

Summary: this study will evaluate the safety and tolerability of mk-4618 when coadministered with antihypertensive agents and will evaluate changes in blood pressure following co-administration of mk-4618 with a beta blocker and a vasodilator. the primary hypothesis of the study is that mk-4618 does not result in a clinically meaningful change in systolic blood pressure relative to placebo when co-administered with a beta-blocker or with amlodipine.


Eligibility criteria:
inclusion criteria: * male or female not of childbearing potential * not a nursing mother * must be on stable dose of a beta blocker (panel a only) or amlodipine (panel b only) for the treatment of hypertension for at least 6 weeks prior to enrollment. must take the designated daily dose of metoprolol or amlodipine for the duration of the study * in good health other than hypertension * nonsmoker * participant has a resting systolic blood pressure \ 95 mmhg and a diastolic blood pressure \ 75 mmhg at prestudy clinical evaluation exclusion criteria: * any illness that might confound the results of the study or pose a risk by participation * history of orthostatic hypotension (decrease in blood pressure upon standing accompanied by symptoms of lightheadedness or dizziness) * history of cancer, excepting certain skin or cervical cancers or cancers that were treated successfully 10 or more years prior to screening * condition for which there is a warning, contraindication, or precaution against the use of extended release metoprolol (panel a) or amlodipine (panel b) * consumes excessive amounts of alcohol or caffeine daily * has multiple and/or severe allergies (including latex allergy) or has had an anaphylactic reaction or significant intolerance to drugs or food * uses illicit drugs or has a history of drug abuse